CN102625803A - 药学上有用的杂环-取代的内酰胺 - Google Patents
药学上有用的杂环-取代的内酰胺 Download PDFInfo
- Publication number
- CN102625803A CN102625803A CN2010800499575A CN201080049957A CN102625803A CN 102625803 A CN102625803 A CN 102625803A CN 2010800499575 A CN2010800499575 A CN 2010800499575A CN 201080049957 A CN201080049957 A CN 201080049957A CN 102625803 A CN102625803 A CN 102625803A
- Authority
- CN
- China
- Prior art keywords
- optionally substituted
- pyrazolo
- alkyl
- compound
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CN(CCC1)CCN1c1nc2c(C=C(CC(N3)=*)C3=O)cn[n]2c(NC2CC2)c1 Chemical compound CN(CCC1)CCN1c1nc2c(C=C(CC(N3)=*)C3=O)cn[n]2c(NC2CC2)c1 0.000 description 9
- UMAKJDOMAFFECH-UXBLZVDNSA-N CC(C)(C)OC(N(C1CC1)c1cc(Cl)nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]12)=O Chemical compound CC(C)(C)OC(N(C1CC1)c1cc(Cl)nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]12)=O UMAKJDOMAFFECH-UXBLZVDNSA-N 0.000 description 5
- VICKFLHKIOKFBP-UHFFFAOYSA-N CC(C)(C)OC(N(C1CC1)c1cc(Cl)nc2c(C=O)cn[n]12)=O Chemical compound CC(C)(C)OC(N(C1CC1)c1cc(Cl)nc2c(C=O)cn[n]12)=O VICKFLHKIOKFBP-UHFFFAOYSA-N 0.000 description 3
- LZEMTVSGYXLANE-UHFFFAOYSA-N CC(C)(C)OC(N(C1CC1)c1cc(-c2cc(CO)ccc2)nc2c(C=O)cn[n]12)=O Chemical compound CC(C)(C)OC(N(C1CC1)c1cc(-c2cc(CO)ccc2)nc2c(C=O)cn[n]12)=O LZEMTVSGYXLANE-UHFFFAOYSA-N 0.000 description 1
- ZURMNIRCABQKGO-WUXMJOGZSA-N CC(C)(C)OC(N(CC1CC1)c1cc(Cl)nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]12)=O Chemical compound CC(C)(C)OC(N(CC1CC1)c1cc(Cl)nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]12)=O ZURMNIRCABQKGO-WUXMJOGZSA-N 0.000 description 1
- QEDMFFLHQMNSMS-FOWTUZBSSA-N CC(NC1CC1)[n]1ncc(/C=C(\CC(N2)=O)/C2=O)c1/N=C(\N)/N(CC1)CCN1c1ccccn1 Chemical compound CC(NC1CC1)[n]1ncc(/C=C(\CC(N2)=O)/C2=O)c1/N=C(\N)/N(CC1)CCN1c1ccccn1 QEDMFFLHQMNSMS-FOWTUZBSSA-N 0.000 description 1
- XZZRIXNZGVPRQE-WEVVVXLNSA-N CC(NC1CC1)[n]1ncc(/C=C(\CC(N2)=O)/C2=O)c1/N=C(\N)/SC Chemical compound CC(NC1CC1)[n]1ncc(/C=C(\CC(N2)=O)/C2=O)c1/N=C(\N)/SC XZZRIXNZGVPRQE-WEVVVXLNSA-N 0.000 description 1
- GAFRYNJDLVWSGB-UXBLZVDNSA-N CC(NCCOC)[n]1ncc(/C=C(\CC(N2)=O)/C2=O)c1/N=C(\N)/SC Chemical compound CC(NCCOC)[n]1ncc(/C=C(\CC(N2)=O)/C2=O)c1/N=C(\N)/SC GAFRYNJDLVWSGB-UXBLZVDNSA-N 0.000 description 1
- HIAJOMNDQLIHKM-OQLLNIDSSA-N CC(c1ccccc1)Nc1nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]2c(NC2CC2)c1 Chemical compound CC(c1ccccc1)Nc1nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]2c(NC2CC2)c1 HIAJOMNDQLIHKM-OQLLNIDSSA-N 0.000 description 1
- BAQKWDBUERDKNN-KPKJPENVSA-N CN(C1CN(C)CC1)c1nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]2c(NC2CC2)c1 Chemical compound CN(C1CN(C)CC1)c1nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]2c(NC2CC2)c1 BAQKWDBUERDKNN-KPKJPENVSA-N 0.000 description 1
- JTDWNZKCOYUQLL-XYOKQWHBSA-N CN(CC1)CCN1c1nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]2c(NC2CC2)c1 Chemical compound CN(CC1)CCN1c1nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]2c(NC2CC2)c1 JTDWNZKCOYUQLL-XYOKQWHBSA-N 0.000 description 1
- VJOMJMKSUUAODM-SDNWHVSQSA-N CN/[O](/C)=C(/C(/C1)=C/c2c3nc(N4CCN(C)CCC4)nc(NC4CC4)[n]3nc2)\NC1=O Chemical compound CN/[O](/C)=C(/C(/C1)=C/c2c3nc(N4CCN(C)CCC4)nc(NC4CC4)[n]3nc2)\NC1=O VJOMJMKSUUAODM-SDNWHVSQSA-N 0.000 description 1
- JJIOUIORTDNEBW-QPJJXVBHSA-N CS(c1nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]2c(NC2CC2)n1)(=O)=O Chemical compound CS(c1nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]2c(NC2CC2)n1)(=O)=O JJIOUIORTDNEBW-QPJJXVBHSA-N 0.000 description 1
- MFSCANSWYNJLBD-QPJJXVBHSA-N CS(c1nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]2c(NC2CC2)n1)=O Chemical compound CS(c1nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]2c(NC2CC2)n1)=O MFSCANSWYNJLBD-QPJJXVBHSA-N 0.000 description 1
- AOOZMPJGSBRIJT-KPKJPENVSA-N Cc(cc(cc1)O)c1Nc1nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]2c(NC2CC2)c1 Chemical compound Cc(cc(cc1)O)c1Nc1nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]2c(NC2CC2)c1 AOOZMPJGSBRIJT-KPKJPENVSA-N 0.000 description 1
- QVRIDBZUABNDCB-RIYZIHGNSA-N Cc(cc1)c(C)cc1Nc1nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]2c(NC2CC2)c1 Chemical compound Cc(cc1)c(C)cc1Nc1nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]2c(NC2CC2)c1 QVRIDBZUABNDCB-RIYZIHGNSA-N 0.000 description 1
- KHNUKQQESKDDIX-YRNVUSSQSA-N O=C(C/C1=C\c(cn[n]2c(NC3CC3)c3)c2nc3N2CCCC2)NC1=O Chemical compound O=C(C/C1=C\c(cn[n]2c(NC3CC3)c3)c2nc3N2CCCC2)NC1=O KHNUKQQESKDDIX-YRNVUSSQSA-N 0.000 description 1
- JQURCFZIYKCONZ-YRNVUSSQSA-N O=C(C/C1=C\c(cn[n]2c(NC3CC3)c3)c2nc3N2CCOCC2)NC1=O Chemical compound O=C(C/C1=C\c(cn[n]2c(NC3CC3)c3)c2nc3N2CCOCC2)NC1=O JQURCFZIYKCONZ-YRNVUSSQSA-N 0.000 description 1
- CYXORCXTCSOLEQ-IZZDOVSWSA-N O=C(C/C1=C\c(cn[n]2c(NC3CC3)c3)c2nc3NCC2OCCC2)NC1=O Chemical compound O=C(C/C1=C\c(cn[n]2c(NC3CC3)c3)c2nc3NCC2OCCC2)NC1=O CYXORCXTCSOLEQ-IZZDOVSWSA-N 0.000 description 1
- FCARHLUFRGTKMV-GXDHUFHOSA-N O=C(C/C1=C\c(cn[n]2c(NC3CC3)c3)c2nc3NCCCN2CCCC2)NC1=O Chemical compound O=C(C/C1=C\c(cn[n]2c(NC3CC3)c3)c2nc3NCCCN2CCCC2)NC1=O FCARHLUFRGTKMV-GXDHUFHOSA-N 0.000 description 1
- GHYFHWPUPHQLCM-BJMVGYQFSA-N O=C(C/C1=C\c(cn[n]2c(NC3CC3)c3)c2nc3Nc(cc2)cc(Cl)c2F)NC1=O Chemical compound O=C(C/C1=C\c(cn[n]2c(NC3CC3)c3)c2nc3Nc(cc2)cc(Cl)c2F)NC1=O GHYFHWPUPHQLCM-BJMVGYQFSA-N 0.000 description 1
- XWKONBZXDWZSIS-YCRREMRBSA-N O=C(C/C1=C\c(cn[n]2c(NCC3CC3)c3)c2nc3Cl)NC1=O Chemical compound O=C(C/C1=C\c(cn[n]2c(NCC3CC3)c3)c2nc3Cl)NC1=O XWKONBZXDWZSIS-YCRREMRBSA-N 0.000 description 1
- PQERTEOTPVFVQM-AWNIVKPZSA-N O=C(C/C1=C\c(cn[n]2c(NCC3CC3)c3)c2nc3Nc2cccc(C(F)(F)F)c2)NC1=O Chemical compound O=C(C/C1=C\c(cn[n]2c(NCC3CC3)c3)c2nc3Nc2cccc(C(F)(F)F)c2)NC1=O PQERTEOTPVFVQM-AWNIVKPZSA-N 0.000 description 1
- UWPXYUTZCCHQNF-DHZHZOJOSA-N O=C(C/C1=C\c2c3nc(N4CCOCCC4)nc(NC4CC4)[n]3nc2)NC1=O Chemical compound O=C(C/C1=C\c2c3nc(N4CCOCCC4)nc(NC4CC4)[n]3nc2)NC1=O UWPXYUTZCCHQNF-DHZHZOJOSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N O=C(C=C1)NC1=O Chemical compound O=C(C=C1)NC1=O PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- MBKDHLFBRIPDCS-VZUCSPMQSA-N OC(C(C1)C=Cc2c1nc[n]2-c1nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]2c(NC2CC2)n1)=O Chemical compound OC(C(C1)C=Cc2c1nc[n]2-c1nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]2c(NC2CC2)n1)=O MBKDHLFBRIPDCS-VZUCSPMQSA-N 0.000 description 1
- RBYRZPQLSANEFN-IZZDOVSWSA-N OC(CCC1)CN1c1nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]2c(NC2CC2)c1 Chemical compound OC(CCC1)CN1c1nc2c(/C=C(\CC(N3)=O)/C3=O)cn[n]2c(NC2CC2)c1 RBYRZPQLSANEFN-IZZDOVSWSA-N 0.000 description 1
- BHPDNFUVYQFFNK-UHFFFAOYSA-N OCN(C(C=C1)=O)C1=O Chemical compound OCN(C(C=C1)=O)C1=O BHPDNFUVYQFFNK-UHFFFAOYSA-N 0.000 description 1
- BLBZYOCJABORDH-VZUCSPMQSA-N Oc(cc1)c(CNc2nc3c(/C=C(\CC(N4)=O)/C4=O)cn[n]3c(NC3CC3)c2)cc1Cl Chemical compound Oc(cc1)c(CNc2nc3c(/C=C(\CC(N4)=O)/C4=O)cn[n]3c(NC3CC3)c2)cc1Cl BLBZYOCJABORDH-VZUCSPMQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24180609P | 2009-09-11 | 2009-09-11 | |
| US61/241,806 | 2009-09-11 | ||
| US37114710P | 2010-08-05 | 2010-08-05 | |
| US61/371,147 | 2010-08-05 | ||
| PCT/US2010/048441 WO2011031979A1 (en) | 2009-09-11 | 2010-09-10 | Pharmaceutically useful heterocycle-substituted lactams |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102625803A true CN102625803A (zh) | 2012-08-01 |
Family
ID=43732815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800499575A Pending CN102625803A (zh) | 2009-09-11 | 2010-09-10 | 药学上有用的杂环-取代的内酰胺 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110071115A1 (https=) |
| EP (1) | EP2475652A1 (https=) |
| JP (1) | JP2013504594A (https=) |
| KR (1) | KR20120104521A (https=) |
| CN (1) | CN102625803A (https=) |
| AU (1) | AU2010292116A1 (https=) |
| BR (1) | BR112012005550A2 (https=) |
| CA (1) | CA2773854A1 (https=) |
| IL (1) | IL218521A0 (https=) |
| IN (1) | IN2012DN03112A (https=) |
| MX (1) | MX2012002994A (https=) |
| SG (1) | SG179083A1 (https=) |
| WO (1) | WO2011031979A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014154026A1 (zh) * | 2013-03-28 | 2014-10-02 | 山东轩竹医药科技有限公司 | PI3K和/或mTOR抑制剂的前药 |
| CN115160341A (zh) * | 2022-07-18 | 2022-10-11 | 中国医学科学院医学实验动物研究所 | 苯并噁嗪类化合物及其药物用途 |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5470557B2 (ja) | 2007-07-26 | 2014-04-16 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の合成 |
| AR069207A1 (es) | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
| US8440658B2 (en) | 2007-12-11 | 2013-05-14 | Vitae Pharmaceuticals, Inc. | Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| TW200934490A (en) | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
| WO2009094169A1 (en) | 2008-01-24 | 2009-07-30 | Vitae Pharmaceuticals, Inc. | Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| US8598160B2 (en) | 2008-02-15 | 2013-12-03 | Vitae Pharmaceuticals, Inc. | Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| EP2291370B1 (en) | 2008-05-01 | 2013-11-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| RU2531272C2 (ru) | 2008-05-01 | 2014-10-20 | Вайтаи Фармасьютиклз, Инк. | Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1 |
| WO2010010157A2 (en) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 |
| NZ590495A (en) | 2008-07-25 | 2012-10-26 | Vitae Pharmaceuticals Inc | Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| EP2323994A1 (en) | 2008-07-25 | 2011-05-25 | Boehringer Ingelheim International GmbH | Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| JP5679997B2 (ja) | 2009-02-04 | 2015-03-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤 |
| US8680093B2 (en) | 2009-04-30 | 2014-03-25 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| US8927539B2 (en) | 2009-06-11 | 2015-01-06 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure |
| WO2011056737A1 (en) | 2009-11-05 | 2011-05-12 | Boehringer Ingelheim International Gmbh | Novel chiral phosphorus ligands |
| EP2576570A1 (en) | 2010-05-26 | 2013-04-10 | Boehringer Ingelheim International GmbH | 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives |
| WO2011159760A1 (en) | 2010-06-16 | 2011-12-22 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
| WO2011161128A1 (en) | 2010-06-25 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders |
| WO2012059416A1 (en) | 2010-11-02 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
| WO2012112568A1 (en) * | 2011-02-14 | 2012-08-23 | The Broad Institute, Inc. | Small molecule inhibitors for treating parasitic infections |
| WO2012170827A2 (en) * | 2011-06-08 | 2012-12-13 | Cylene Pharmaceuticals, Inc. | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors |
| WO2013051672A1 (ja) * | 2011-10-04 | 2013-04-11 | 株式会社ヤクルト本社 | チアゾリジン誘導体又はその塩を有効成分とする医薬品 |
| JP6280546B2 (ja) | 2012-06-26 | 2018-02-14 | デル マー ファーマシューティカルズ | ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 |
| TW201414737A (zh) * | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| PE20191245A1 (es) | 2013-01-15 | 2019-09-18 | Incyte Holdings Corp | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim |
| KR20160061911A (ko) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
| EA201690458A1 (ru) | 2013-08-23 | 2016-07-29 | Инсайт Корпорейшн | Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| SI3658557T1 (sl) | 2017-07-28 | 2024-10-30 | Takeda Pharmaceutical Company Limited | Zaviralci TYK2 in njihova uporaba |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| US11071727B2 (en) | 2018-01-26 | 2021-07-27 | Northwestern University | Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors |
| CA3116731A1 (en) | 2018-10-19 | 2020-04-23 | Senhwa Biosciences, Inc. | Combinations for immune-modulation in cancer treatment |
| EP3771711A1 (en) | 2019-07-29 | 2021-02-03 | Bayer Animal Health GmbH | Pyrazole derivatives for controlling arthropods |
| TWI885039B (zh) | 2020-01-13 | 2025-06-01 | 美商邊際分析公司 | 經取代吡唑并嘧啶及其用途 |
| IL297327B2 (en) | 2020-05-01 | 2026-01-01 | Gilead Sciences Inc | 4,2-dioxopyrimidine compounds CD73 inhibitors |
| TW202313052A (zh) * | 2021-06-08 | 2023-04-01 | 美商邊際分析公司 | 使用經取代吡唑并嘧啶之病毒感染治療及方法 |
| JP7787991B2 (ja) * | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1880317A (zh) * | 2002-09-04 | 2006-12-20 | 先灵公司 | 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶 |
| US20080045496A1 (en) * | 2006-08-09 | 2008-02-21 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US20080275043A1 (en) * | 2004-10-29 | 2008-11-06 | Thomas Daniel Aicher | Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 |
| CN101495481A (zh) * | 2006-05-22 | 2009-07-29 | 先灵公司 | 作为CDK抑制剂的吡唑并[1,5-α]嘧啶 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998424A (en) * | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
| MXPA05002571A (es) * | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
| BRPI0616985B1 (pt) * | 2005-10-06 | 2021-10-26 | Merck Sharp & Dohme Corp. | Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto |
| US8372851B2 (en) * | 2005-10-21 | 2013-02-12 | Exelixis, Inc. | Pyrazolo pyrimidines as casein kinase II (CK2) modulators |
| DK2526933T3 (en) * | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
-
2010
- 2010-09-10 SG SG2012016929A patent/SG179083A1/en unknown
- 2010-09-10 IN IN3112DEN2012 patent/IN2012DN03112A/en unknown
- 2010-09-10 CN CN2010800499575A patent/CN102625803A/zh active Pending
- 2010-09-10 AU AU2010292116A patent/AU2010292116A1/en not_active Abandoned
- 2010-09-10 EP EP10816161A patent/EP2475652A1/en not_active Withdrawn
- 2010-09-10 US US12/879,851 patent/US20110071115A1/en not_active Abandoned
- 2010-09-10 KR KR1020127009217A patent/KR20120104521A/ko not_active Withdrawn
- 2010-09-10 WO PCT/US2010/048441 patent/WO2011031979A1/en not_active Ceased
- 2010-09-10 BR BR112012005550A patent/BR112012005550A2/pt not_active IP Right Cessation
- 2010-09-10 MX MX2012002994A patent/MX2012002994A/es not_active Application Discontinuation
- 2010-09-10 CA CA2773854A patent/CA2773854A1/en not_active Abandoned
- 2010-09-10 JP JP2012528930A patent/JP2013504594A/ja active Pending
-
2012
- 2012-03-07 IL IL218521A patent/IL218521A0/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1880317A (zh) * | 2002-09-04 | 2006-12-20 | 先灵公司 | 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶 |
| US20080275043A1 (en) * | 2004-10-29 | 2008-11-06 | Thomas Daniel Aicher | Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 |
| CN101495481A (zh) * | 2006-05-22 | 2009-07-29 | 先灵公司 | 作为CDK抑制剂的吡唑并[1,5-α]嘧啶 |
| US20080045496A1 (en) * | 2006-08-09 | 2008-02-21 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014154026A1 (zh) * | 2013-03-28 | 2014-10-02 | 山东轩竹医药科技有限公司 | PI3K和/或mTOR抑制剂的前药 |
| CN105121442A (zh) * | 2013-03-28 | 2015-12-02 | 山东轩竹医药科技有限公司 | PI3K和/或mTOR抑制剂的前药 |
| CN105121442B (zh) * | 2013-03-28 | 2017-05-17 | 山东轩竹医药科技有限公司 | PI3K和/或mTOR抑制剂的前药 |
| CN115160341A (zh) * | 2022-07-18 | 2022-10-11 | 中国医学科学院医学实验动物研究所 | 苯并噁嗪类化合物及其药物用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010292116A1 (en) | 2012-05-03 |
| BR112012005550A2 (pt) | 2015-09-08 |
| US20110071115A1 (en) | 2011-03-24 |
| KR20120104521A (ko) | 2012-09-21 |
| CA2773854A1 (en) | 2011-03-17 |
| WO2011031979A1 (en) | 2011-03-17 |
| EP2475652A1 (en) | 2012-07-18 |
| SG179083A1 (en) | 2012-04-27 |
| MX2012002994A (es) | 2012-07-17 |
| IL218521A0 (en) | 2012-07-31 |
| JP2013504594A (ja) | 2013-02-07 |
| IN2012DN03112A (https=) | 2015-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102625803A (zh) | 药学上有用的杂环-取代的内酰胺 | |
| KR101851130B1 (ko) | Ｃｋ2 억제제로서 피라졸로피리미딘 및 관련된 헤테로사이클 | |
| US8367681B2 (en) | Pyrazolopyrimidines and related heterocycles as kinase inhibitors | |
| US20100298302A1 (en) | Novel protein kinase modulators | |
| CN102647906A (zh) | 三环化合物及其药学用途 | |
| CN102647904A (zh) | 新型三环蛋白激酶调节剂 | |
| MXPA01011832A (es) | Inhibidores de cinasas, de pirrolotriazina. | |
| CN102596969A (zh) | 用作蛋白激酶调节剂的稠合喹啉类化合物 | |
| KR20160086930A (ko) | 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120801 |